DEVELOPMENT OF FORMULATION AND EVALUATION OF TERBUTALINE SULPHATE AND AMBROXOL HYDROCHLORIDE ORAL NANOSUSPENSION
The aim of the present investigation was to develop, formulate and evaluation of Terbutaline sulphate and Ambroxol hydrochloride nanosuspension for treatment of bronchial asthma. Terbutaline sulphate is a selective beta-2(β2) adrenergic agonist used as anti-asthmatic. Ambroxol hydrochloride is a mucolytic agent used to treat respiratory diseases associated with viscid or excessive mucus accumulated in respiratory tract. The present research involved to find out the effect of different polymer and their ratio on the formulation of Terbutaline sulphate and Ambroxol hydrochloride oral nanosuspension. The prepared nanosuspension were evaluated for particle size, polydispersity index, zeta potential, SEM analysis, Saturation solubility, drug content, viscosity, Invitro drug release studies, stability studies. Saturation solubility studies and Invitro drug release studies shows that the prepared nanosuspension has increased solubility and dissolution rate compared to pure drug. Among all the formulations, formulation F2 has shown the better results like average particle size of 78.5 nm, the Polydispersity index was found to be 1.023, zeta potential was found to be 27.3mv and the drug release of 98.8% for terbutaline sulphate and 97.3% for Ambroxol hydrochloride up to the 8th hour. Stability studies were carried out and it is evident that the F2 was found to be more stable in refrigerated temperature than room temperature